Positron's Attrius Receives Health Canada Approval

FISHERS, Ind., Dec. 14, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce today that on December 12, 2011, the Company's Positron Emission Tomography Scanner(s) Attrius & Attrius L have received approval for sale in Canada.

The Medical Device License from Health Canada was granted to the Attrius systems manufacturer, Neusoft Positron Medical Systems. NPMS is a joint venture between Neusoft Medical Systems of Shenyang, China and Positron Corporation. Positron Corporation has exclusive rights to sell Attrius in North America.    

"We are pleased that our scanners are approved for the Health Canada system. It is great step forward for our technology and our integrated PET solutions," said Patrick G. Rooney, CEO of Positron.  "The Canadian market is vast with a sophisticated approach to health care and is a market that requires the full cardiac PET solution. We have developed leading products and are integrating key segments critical to being able to offer the complete value chain.  The Canadian market is very important to us and we intend to have a very strong presence throughout the country."   

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation